Search

Your search keyword '"Isayeva, M"' showing total 16 results
Start Over Author "Isayeva, M"
16 results on '"Isayeva, M"'

1. Arterial hypertension management in patients with confirmed coronary heart disease: how far are we from meeting prevention goals?

Author

Gabulova, R, primary, Marza-Florensa, A, additional, Isayeva, M, additional, Rahimov, U, additional, Gahramanova, S, additional, Alaskarova, S H, additional, Ibrahimov, F, additional, Aliyev, F, additional, Imanov, G, additional, Musayeva, A, additional, Rasulova, R, additional, Zarbaliyeva, N, additional, Abasov, R, additional, Graham, I, additional, and Grobbee, D E, additional

Published
2023
Full Text
View/download PDF

6. Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry

Author

Komajda, M. Schöpe, J. Wagenpfeil, S. Tavazzi, L. Böhm, M. Ponikowski, P. Anker, S.D. Filippatos, G.S. Cowie, M.R. Aleksanyan, A. Atayan, L. Avetisyan, A. Davtyan, N. Drambyan, M. Gevorgyan, K. Grigoryan, M. Hakobyan, Z. Hayrapetyan, H. Kocharyan, L. Kramarevskaya, T. Melqonyan, A. Muradyan, F. Nanyan, R. Ordyan, A. Ordyan, M. Piruzyan, A. Podosyan, G. Safaryan, K. Sargsyan, T. Sarkisyan, A. Sisakyan, H. Ter-Grigoryan, V. Ustyan, T. Alexopoulos, C. Amerena, J. Arstall, M. Ayres, B. Barron, G. Beltrame, J. Bou-Samra, J. Brown, M. Cross, D. Dwyer, N. Eccleston, N. Hare, D. Ho, B. Hopper, I. Jackson, B. Korczyk, D. Lattimore, J.D. Levendel, A. Macfadyen, R. Pandeli, V. Playford, D. Richardson, M. Senior, J.A. Shah, A. Shetty, P. Soward, A. Srivastava, P. Swale, M. Vogl, E. Wai, B. William, M. Worthington, A. Wright, S. Brunner, B. Fuhrmann, W. Horer, L. Maca, T. Nahler, A. Ortner, H. Racz, G. Scheibner, P. Sebald, C. Abdullayev, A. Abdullayev, R. Ahmadov, A. Alakbarov, E. Aliyev, F. Aliyev, F. Bakhshaliyev, A. Bakhshiyev, M. Dadashova, G. Dashdamirov, R. Faradjova, N. Guliyev, A. Guliyev, F. Guliyeva, S. Hajiyev, G. Ibrahimov, F. Imanov, G. Isayeva, A. Isayeva, M. Jabrailova, U. Jafarov, R. Jahangirov, T. Khalilov, A. Khalilov, S. Mehdiyev, S. Najafov, R. Samedova, H. Shahhuseynov, S. Yusifly, R. Yusifov, T. Zahidova, K. Zeynalov, A. Abdullatif, A. Al-Banna, R. Haiky, W. Husain, A. Jamsheer, A. Barbuk, O. Belskaya, M. Borodko, V. Kurlianskaya, A. Mackevich, S. Mankevich, N. Moroz-Vodolazhskaya, N. Ravtovich, O. Saevich, A. Troyanova, T. Chughtai, A. Johar, S. Luqman, N. Nair, T.C.-R. Deyoung, P. Ezekowitz, J. Frenette, M. Howlett, J. Huynh, T. Nguyen, V. Toma, M. Orenstein, T. Rinne, M.R.C. Virani, S. Zieroth, S. Ailiman, M. Cong, H. Ding, W. Dong, W. Dong, Y. Gao, C. Li, L. Li, Z. Liang, Y. Liu, X. Liu, S. Luo, S. Shi, H. Tian, Q. Wang, D. Wang, J. Wei, M. Wu, C. Xu, D. Yang, X. Yang, Z. Zhang, C. Zhang, Q. Zhang, Y. Zhang, R. Zheng, Y. Zhao, L. Zhou, J. Buch, P. Davidsen, F. Eiskjær, H. Bruun, N.E. Kragh-Thomsen, N.E. Franow, H. Køber, L. Korup, E. Madsen, B.K. Mikkelsen, K. Nielsen, K.A. Nørgaard, A. Refsgaard, J. Rickers, H. Kaiser, P. Sykulski, R. Zeuthen, E.L. El Fottoh, A.A. El Badry, M. El Hady, Y.A. El Kady, E. El Khatib, H. Fawzy, M. Hegazy, H. Salama, M.K. Mortada, A. Mostafa, T. Mwafy, A. Ossama, M. Samir, S. Seleem, M. Sobhy, B. Bregadze, G. Chelidze, K. Chumburidze, V. Jalabadze, K. Khabeishvili, G. Kiphiani, Z. Klimiashvili, Z. Kvitsiani, A. Mamatsashvili, M. Melia, I.M.A. Oragvelidze, T. Orjonikidze, S. Paposhvili, K. Petriashvili, S. Phaghava, Z. Shushania, M. Tsetskhladze, E. Tsinamdzgvishvili, B. Abdel-Qader, M. Al-Zoebi, A. Böhm, G. Bosch, R. Brune, S. Bunge, K. Dominick, K. Duda, S. Erdogan, A.E. Faber, G. Fach, C. Fechtrup, C. Frickel, S. Giokoglu, K. Haas, J. Hagenow, A. Haj-Yehia, A. Hansen, C. Hartung, W.M. Hauser, E.R. Hofmeister, A. Hohensee, H. Hüttemann, M. Keim, M. Krämer, A. Langwasser, K. Lodde, B.P. Lorch, G. Lüer, C. Müller, K. Placke, J. Plesch, B. Potolidis, L. Richter, F. Rieker, W.A. Schlichting, J. Stenzel, G. Theuer, J.D. Marcin, A. Warkentin, R. Wegner, M. Wilke, A. Agrafiotis, I. Aleksandridis, I. Farmakis, D. Giannakoulas, G. Karavidas, A. Lamprou, A. Ninios, V. Panagiotopoulos, K. Papadopoulos, K. Siachos, S. Dékány, M. Borbéy, A. Borsányi, T. Forster, T. Gavallér, H. Gyuricza, I. Heltai, K. Herczeg, B. HŐgye, M. Losonczi, I. Merkely, B. Metz, E. Muk, B. Nagy, K. Ökrös, M. Piry, K. Poós, G. Sárszegi, Z. Somogyi, T. Sziliczei-Németh, E. Tátrai, T. Zima, E. Zsigmond, A. Daly, C. Mahon, N. Meany, B. Abbdi, I. Awaysheh, R. Azouka, M. Hamoudeh, S. Nammas, A. Okkeh, O. Aimakova, G. Ismagulova, Z. Issabekova, A. Junusbekova, G.A. Koshumbayeva, K. Madaliyev, K. Mekebekova, D. Mukatova, A. Ospanova, G. Sadvakassova, G. Sunkarbekova, Z. Yegorova, Y. Zhangelova, S. Kim, K.H. Al-Mutairi, M. Gaber, Y. Ghali, I. Ghanem, A. Hafez, H. Haiba, M. Koushy, T. Mahmoud, A. Raafat, G. Sallam, M. Senousi, O. Soliman, M. Massih, T.A. Ali, S.A. Jaoude, S.A. Azzi, N. Badaoui, G. Bayeh, H. Beydoun, A. Chammas, E. Dib, H. Gebran, M. Ghanem, G. Haidar, H. Hamadeh, M. Hamoui, O. Hobeika, R. Jazra, C. Kabbani, S. Kadri, Z. Karanaminassian, R. Kassab, R. Kleit, M. Mansour, H. Mousallem, N. Semaan, C. Simonian, A. Sarkis, A. Succar, S. Zalloum, R. Zind, R. Anusauskiene, J. Grigaliuniene, A. Karaliute, R. Kavoliuniene, A. Kozlovaite, V. Miliuniene, D. Rinkuniene, D. Rudys, A. Stasaityte, D. Aziz, F.A.A. Rahim, A.A.A. Ahmad, R. Ahmadsah, S.H.K.A. Ang, C.C. Ang, S.H. Cham, Y.L. Chee, K.H. Chooi, K.C. Chu, C.M. Fam, T.L. Fong, A. Ismail, O. Ismail, J.R. Kamarulzaman, M.H. Kasim, S.S. Khiew, N.Z. Krishnan, C. Krishinan, S. Lau, G. Lee, L.Y. Liew, H.B. Lim, C.W. Mahendran, K. Dass, R.D.M. Mohamad, R. Arshad, M.K.M. Unit, H.M. Mustapha, Z. Ng, W.K. Ong, T.K. Oon, Y.Y. Ramli, A.W. Ramanathan, G.R.L. Ross, N.T. Said, A. Sarwar, M. Tan, E. Tan, S.K. Voon, C.Y. Yusoff, M.R. Abidin, H.A.Z. Chua, S.K. Yew, K.L. Amin, N.H.M. Kandiah, K. Chong, L.A. Mohamed, M.S. Lim, B.K. Koh, K.T. Low, D.W. Abdelkhirane, C. Allali, Y. Askour, M. Balafrej, K. Bendagha, N. Bendriss, L. Benjelloun, H. Chaib, A. Cherradi, G. Cherti, M. Chtioui, M. El Belghiti, A.R. Fihri, O.F. Habbal, R. El Hattaoui, M. Khatouri, A. Kheyi, J. Kriem, J. Soufiane, N. Soufiani, A. Zaimi, S. Adamczyk-Kot, D. Barg, Z. Bartkowiak, R. Braciszewicz, W. Czajkowska, E. Dudek-Niechciał, M. Grzelakowski, P. Jarosik, Z. Jerzykowska, O. Koprowski, P. Krysiak, W. Łajkowski, Z. Ziemlewska-Krawczyk, E. Lelonek, M. Lewicka, E. Płonka, J. Sadowski, J. StĘpieŃ-Adamczewska, V. Szponar, J. WrzesiŃski, K. Brito, D.A. Araújo, I. Figueiredo, J.P.A. Campelo, M.B. Sardinha, P.M.B. Fernando, P. de Brito Domingues Sanches Peres de Noronha, M.A. Baptista, S.B.C. Cardoso Pinto, J.P. Piçarra, B.M.C. Farto e Abreu, P. da Fonseca, M.C.F.G. Soares, A.I.C.G.O. Resende, J.D.A. Durão, D.L. Nascimento, A.I.F.V. Bernardes, E.L.M.O. Marques, F. Ramos, M.A.N. Sargento, L.J.M. dos Santos, J.P.F. Raimundo, A. da Luz Ventosa, A.M.S. Sarmento, P. Aguiar, C.M.T. Ahmed, E. Al-Suwaidi, J. Al Dabdoob, W. Badr, A. Gomaa, M. Albu, M. Antohi, I. Apavaloaei, C. Ardelean, A. Badea, G. Bicescu, G. Blaj, C. Bogdan, L. Bucatanschi, M. Buzea, A. Calarasu, V. Catinean, S. Christodorescu, R. Cocoi, D. Costache, L. Cretu, D. Crisu, D. Dima-Cozma, C. Dumitrescu, S. Enache, V. Firastrau, V. Frigy, A. Gherghina, A. Girbea, S. Gutu, A. Horovitz, M. Hortopan, G. Istratoaie, O. Jianu, C. Jinga, L. Lighezan, D. Luka, A. Magheru, S. Mercea, D. Miklos, K. Moga, R. Oprea, N. Paraschiv, D.M. Pop, D. Rusu, R. Sirbu, I. Socoteanu, E. Stanciulescu, G. Suteu, A. Tetiu, O. Traistaru, A. Tudoran, M. Turiceanu, M.C. Viinkler, L. Adonina, E. Akinina, S. Alferov, P. Arkhipov, M. Aroutunov, G. Babkin, A. Barbashina, T. Bochkareva, J. Boldueva, S. Bukhonkina, J. Chumakova, S.G. Fayans, I. Furmenko, G. Galyavich, A. Grinstein, Y. Klein, G. Kastanayan, A. Kazachkova, T. Korolev, S. Koshelskaya, O. Kosmacheva, E. Koziolova, N. Kuimov, A. Kushnarenko, N. Lebedev, P. Matushin, G. Mineeva, E. Motylev, I. Nedbaykin, A. Nevzorova, V. Rachkova, S. Rebrov, A. Reznik, I. Saiganov, S. Sayfutdinov, R. Schekotov, V. Serdechnaya, E. Shalaev, S. Shtegman, O. Sitnikova, M. Smolenskaya, O. Sulimov, V. Tarlovskaya, E. Temnikova, E. Timonin, D. Tolstov, S. Uskatch, T. Ustyuzhanin, V. Valeeva, R. Vasyuk, Y. Viktorova, I. Yakushin, S. Zadionchenko, V. Zateischikov, D. Zhirov, I. Bollová, D. Dulková, K. Fazekaš, F. Hermel, I. KŇazeje, M. NedĚĽová, I. Nociar, J. Procházka, L. Pundová, L. Slanina, M. Varga, I. Almenar, L. Beltrán, P. Cobo, M. Delgado, J. Enjuanes, C. Garrido, I. Gómez, M.A. Manito, N. Marzal, D. Murga, N. Ocampo, M. Pérez, J. Sánchez, I. Buakhamsri, A. Leemasawat, K. Kanoksilp, A. Kiatchoosakun, S. Phrommintikul, A. Porapakkham, P. Rodprasert, S. Senthong, V. Wongcharoen, W. Wongwantanee, S. Bahadir, H. Emül, A. Gokce, M. Gurcagan, A. Kaya, O.K. Keser, A. Pinar, P. Taș, M.H. Tosun, H.B. Yazlar, A.S. Yilmaz, S. Yuksel, Y. Bagriy, A. Ivchyna, N. Lyashenko, A. Matviychuk, N. Shchukina, O. Tkach, N. Tseluyko, V. Vasylieva, L. Abdallah, A. Agrawal, A. Basleeb, F. Bazargani, N. Hatou, E. Al Kaddour, A.R. Al Kasser, M. Al Mulla, A. Radaideh, G. Salustri, A. on behalf of the QUALIFY Investigators

Abstract

Background: Physicians' adherence to guideline-recommended therapy is associated with short-term clinical outcomes in heart failure (HF) with reduced ejection fraction (HFrEF). However, its impact on longer-term outcomes is poorly documented. Here, we present results from the 18-month follow-up of the QUALIFY registry. Methods and results: Data at 18 months were available for 6118 ambulatory HFrEF patients from this international prospective observational survey. Adherence was measured as a continuous variable, ranging from 0 to 1, and was assessed for five classes of recommended HF medications and dosages. Most deaths were cardiovascular (CV) (228/394) and HF-related (191/394) and the same was true for unplanned hospitalizations (1175 CV and 861 HF-related hospitalizations, out of a total of 1541). According to univariable analysis, CV and HF deaths were significantly associated with physician adherence to guidelines. In multivariable analysis, HF death was associated with adherence level [subdistribution hazard ratio (SHR) 0.93, 95% confidence interval (CI) 0.87–0.99 per 0.1 unit adherence level increase; P = 0.034] as was composite of HF hospitalization or CV death (SHR 0.97, 95% CI 0.94–0.99 per 0.1 unit adherence level increase; P = 0.043), whereas unplanned all-cause, CV or HF hospitalizations were not (all-cause: SHR 0.99, 95% CI 0.9–1.02; CV: SHR 0.98, 95% CI 0.96–1.01; and HF: SHR 0.99, 95% CI 0.96–1.02 per 0.1 unit change in adherence score; P = 0.52, P = 0.2, and P = 0.4, respectively). Conclusion: These results suggest that physicians' adherence to guideline-recommended HF therapies is associated with improved outcomes in HFrEF. Practical strategies should be established to improve physicians' adherence to guidelines. © 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology

Published
2019

8. Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry

Author

Komajda, M. Schöpe, J. Wagenpfeil, S. Tavazzi, L. Böhm, M. Ponikowski, P. Anker, S.D. Filippatos, G.S. Cowie, M.R. Aleksanyan, A. Atayan, L. Avetisyan, A. Davtyan, N. Drambyan, M. Gevorgyan, K. Grigoryan, M. Hakobyan, Z. Hayrapetyan, H. Kocharyan, L. Kramarevskaya, T. Melqonyan, A. Muradyan, F. Nanyan, R. Ordyan, A. Ordyan, M. Piruzyan, A. Podosyan, G. Safaryan, K. Sargsyan, T. Sarkisyan, A. Sisakyan, H. Ter-Grigoryan, V. Ustyan, T. Alexopoulos, C. Amerena, J. Arstall, M. Ayres, B. Barron, G. Beltrame, J. Bou-Samra, J. Brown, M. Cross, D. Dwyer, N. Eccleston, N. Hare, D. Ho, B. Hopper, I. Jackson, B. Korczyk, D. Lattimore, J.D. Levendel, A. Macfadyen, R. Pandeli, V. Playford, D. Richardson, M. Senior, J.A. Shah, A. Shetty, P. Soward, A. Srivastava, P. Swale, M. Vogl, E. Wai, B. William, M. Worthington, A. Wright, S. Brunner, B. Fuhrmann, W. Horer, L. Maca, T. Nahler, A. Ortner, H. Racz, G. Scheibner, P. Sebald, C. Abdullayev, A. Abdullayev, R. Ahmadov, A. Alakbarov, E. Aliyev, F. Aliyev, F. Bakhshaliyev, A. Bakhshiyev, M. Dadashova, G. Dashdamirov, R. Faradjova, N. Guliyev, A. Guliyev, F. Guliyeva, S. Hajiyev, G. Ibrahimov, F. Imanov, G. Isayeva, A. Isayeva, M. Jabrailova, U. Jafarov, R. Jahangirov, T. Khalilov, A. Khalilov, S. Mehdiyev, S. Najafov, R. Samedova, H. Shahhuseynov, S. Yusifly, R. Yusifov, T. Zahidova, K. Zeynalov, A. Abdullatif, A. Al-Banna, R. Haiky, W. Husain, A. Jamsheer, A. Barbuk, O. Belskaya, M. Borodko, V. Kurlianskaya, A. Mackevich, S. Mankevich, N. Moroz-Vodolazhskaya, N. Ravtovich, O. Saevich, A. Troyanova, T. Chughtai, A. Johar, S. Luqman, N. Nair, T.C.-R. Deyoung, P. Ezekowitz, J. Frenette, M. Howlett, J. Huynh, T. Nguyen, V. Toma, M. Orenstein, T. Rinne, M.R.C. Virani, S. Zieroth, S. Ailiman, M. Cong, H. Ding, W. Dong, W. Dong, Y. Gao, C. Li, L. Li, Z. Liang, Y. Liu, X. Liu, S. Luo, S. Shi, H. Tian, Q. Wang, D. Wang, J. Wei, M. Wu, C. Xu, D. Yang, X. Yang, Z. Zhang, C. Zhang, Q. Zhang, Y. Zhang, R. Zheng, Y. Zhao, L. Zhou, J. Buch, P. Davi and Komajda, M. Schöpe, J. Wagenpfeil, S. Tavazzi, L. Böhm, M. Ponikowski, P. Anker, S.D. Filippatos, G.S. Cowie, M.R. Aleksanyan, A. Atayan, L. Avetisyan, A. Davtyan, N. Drambyan, M. Gevorgyan, K. Grigoryan, M. Hakobyan, Z. Hayrapetyan, H. Kocharyan, L. Kramarevskaya, T. Melqonyan, A. Muradyan, F. Nanyan, R. Ordyan, A. Ordyan, M. Piruzyan, A. Podosyan, G. Safaryan, K. Sargsyan, T. Sarkisyan, A. Sisakyan, H. Ter-Grigoryan, V. Ustyan, T. Alexopoulos, C. Amerena, J. Arstall, M. Ayres, B. Barron, G. Beltrame, J. Bou-Samra, J. Brown, M. Cross, D. Dwyer, N. Eccleston, N. Hare, D. Ho, B. Hopper, I. Jackson, B. Korczyk, D. Lattimore, J.D. Levendel, A. Macfadyen, R. Pandeli, V. Playford, D. Richardson, M. Senior, J.A. Shah, A. Shetty, P. Soward, A. Srivastava, P. Swale, M. Vogl, E. Wai, B. William, M. Worthington, A. Wright, S. Brunner, B. Fuhrmann, W. Horer, L. Maca, T. Nahler, A. Ortner, H. Racz, G. Scheibner, P. Sebald, C. Abdullayev, A. Abdullayev, R. Ahmadov, A. Alakbarov, E. Aliyev, F. Aliyev, F. Bakhshaliyev, A. Bakhshiyev, M. Dadashova, G. Dashdamirov, R. Faradjova, N. Guliyev, A. Guliyev, F. Guliyeva, S. Hajiyev, G. Ibrahimov, F. Imanov, G. Isayeva, A. Isayeva, M. Jabrailova, U. Jafarov, R. Jahangirov, T. Khalilov, A. Khalilov, S. Mehdiyev, S. Najafov, R. Samedova, H. Shahhuseynov, S. Yusifly, R. Yusifov, T. Zahidova, K. Zeynalov, A. Abdullatif, A. Al-Banna, R. Haiky, W. Husain, A. Jamsheer, A. Barbuk, O. Belskaya, M. Borodko, V. Kurlianskaya, A. Mackevich, S. Mankevich, N. Moroz-Vodolazhskaya, N. Ravtovich, O. Saevich, A. Troyanova, T. Chughtai, A. Johar, S. Luqman, N. Nair, T.C.-R. Deyoung, P. Ezekowitz, J. Frenette, M. Howlett, J. Huynh, T. Nguyen, V. Toma, M. Orenstein, T. Rinne, M.R.C. Virani, S. Zieroth, S. Ailiman, M. Cong, H. Ding, W. Dong, W. Dong, Y. Gao, C. Li, L. Li, Z. Liang, Y. Liu, X. Liu, S. Luo, S. Shi, H. Tian, Q. Wang, D. Wang, J. Wei, M. Wu, C. Xu, D. Yang, X. Yang, Z. Zhang, C. Zhang, Q. Zhang, Y. Zhang, R. Zheng, Y. Zhao, L. Zhou, J. Buch, P. Davi

Abstract

Background: Physicians' adherence to guideline-recommended therapy is associated with short-term clinical outcomes in heart failure (HF) with reduced ejection fraction (HFrEF). However, its impact on longer-term outcomes is poorly documented. Here, we present results from the 18-month follow-up of the QUALIFY registry. Methods and results: Data at 18 months were available for 6118 ambulatory HFrEF patients from this international prospective observational survey. Adherence was measured as a continuous variable, ranging from 0 to 1, and was assessed for five classes of recommended HF medications and dosages. Most deaths were cardiovascular (CV) (228/394) and HF-related (191/394) and the same was true for unplanned hospitalizations (1175 CV and 861 HF-related hospitalizations, out of a total of 1541). According to univariable analysis, CV and HF deaths were significantly associated with physician adherence to guidelines. In multivariable analysis, HF death was associated with adherence level [subdistribution hazard ratio (SHR) 0.93, 95% confidence interval (CI) 0.87–0.99 per 0.1 unit adherence level increase; P = 0.034] as was composite of HF hospitalization or CV death (SHR 0.97, 95% CI 0.94–0.99 per 0.1 unit adherence level increase; P = 0.043), whereas unplanned all-cause, CV or HF hospitalizations were not (all-cause: SHR 0.99, 95% CI 0.9–1.02; CV: SHR 0.98, 95% CI 0.96–1.01; and HF: SHR 0.99, 95% CI 0.96–1.02 per 0.1 unit change in adherence score; P = 0.52, P = 0.2, and P = 0.4, respectively). Conclusion: These results suggest that physicians' adherence to guideline-recommended HF therapies is associated with improved outcomes in HFrEF. Practical strategies should be established to improve physicians' adherence to guidelines. © 2019 The Authors. European Journal of Heart Failure © 2019 European Society of Cardiology

Published
2019

9. Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry

Author

Komajda, M, Schöpe, J, Wagenpfeil, S, Tavazzi, L, Böhm, M, Ponikowski, P, Anker, SD, Filippatos, GS, Cowie, MR, Aleksanyan, A, Atayan, L, Avetisyan, A, Davtyan, N, Drambyan, M, Gevorgyan, K, Grigoryan, M, Hakobyan, Z, Hayrapetyan, H, Kocharyan, L, Kramarevskaya, T, Melqonyan, A, Muradyan, F, Nanyan, R, Ordyan, A, Ordyan, M, Piruzyan, A, Podosyan, G, Safaryan, K, Sargsyan, T, Sarkisyan, A, Sisakyan, H, Ter-Grigoryan, V, Ustyan, T, Alexopoulos, C, Amerena, John, Arstall, M, Ayres, B, Barron, G, Beltrame, J, Bou-Samra, J, Brown, M, Cross, D, Dwyer, N, Eccleston, N, Hare, D, Ho, B, Hopper, I, Jackson, B, Korczyk, D, Lattimore, JD, Levendel, A, Macfadyen, R, Pandeli, V, Playford, D, Richardson, M, Senior, JA, Shah, A, Shetty, P, Soward, A, Srivastava, P, Swale, M, Vogl, E, Wai, B, William, M, Worthington, A, Wright, S, Brunner, B, Fuhrmann, W, Horer, L, Maca, T, Nahler, A, Ortner, H, Racz, G, Scheibner, P, Sebald, C, Abdullayev, A, Abdullayev, R, Ahmadov, A, Alakbarov, E, Aliyev, F, Bakhshaliyev, A, Bakhshiyev, M, Dadashova, G, Dashdamirov, R, Faradjova, N, Guliyev, A, Guliyev, F, Guliyeva, S, Hajiyev, G, Ibrahimov, F, Imanov, G, Isayeva, A, Isayeva, M, Jabrailova, U, Jafarov, R, Jahangirov, T, Khalilov, A, Khalilov, S, Mehdiyev, S, Komajda, M, Schöpe, J, Wagenpfeil, S, Tavazzi, L, Böhm, M, Ponikowski, P, Anker, SD, Filippatos, GS, Cowie, MR, Aleksanyan, A, Atayan, L, Avetisyan, A, Davtyan, N, Drambyan, M, Gevorgyan, K, Grigoryan, M, Hakobyan, Z, Hayrapetyan, H, Kocharyan, L, Kramarevskaya, T, Melqonyan, A, Muradyan, F, Nanyan, R, Ordyan, A, Ordyan, M, Piruzyan, A, Podosyan, G, Safaryan, K, Sargsyan, T, Sarkisyan, A, Sisakyan, H, Ter-Grigoryan, V, Ustyan, T, Alexopoulos, C, Amerena, John, Arstall, M, Ayres, B, Barron, G, Beltrame, J, Bou-Samra, J, Brown, M, Cross, D, Dwyer, N, Eccleston, N, Hare, D, Ho, B, Hopper, I, Jackson, B, Korczyk, D, Lattimore, JD, Levendel, A, Macfadyen, R, Pandeli, V, Playford, D, Richardson, M, Senior, JA, Shah, A, Shetty, P, Soward, A, Srivastava, P, Swale, M, Vogl, E, Wai, B, William, M, Worthington, A, Wright, S, Brunner, B, Fuhrmann, W, Horer, L, Maca, T, Nahler, A, Ortner, H, Racz, G, Scheibner, P, Sebald, C, Abdullayev, A, Abdullayev, R, Ahmadov, A, Alakbarov, E, Aliyev, F, Bakhshaliyev, A, Bakhshiyev, M, Dadashova, G, Dashdamirov, R, Faradjova, N, Guliyev, A, Guliyev, F, Guliyeva, S, Hajiyev, G, Ibrahimov, F, Imanov, G, Isayeva, A, Isayeva, M, Jabrailova, U, Jafarov, R, Jahangirov, T, Khalilov, A, Khalilov, S, and Mehdiyev, S

Published
2019

12. Autoantibodies with Different Level of Specificity and Functionality in the Pathogenesis and Diagnostics of Autoimmune Thyroid Disorders

Author

Paltsev M, Isayeva M, Anziferov M, Suchkova E, Tsagurija K, Suchkov S, and Bogatireva S

Subjects
business.industry, Immunology, Medicine, General Medicine, RC648-665, business, Molecular biology, Diseases of the endocrine glands. Clinical endocrinology
Abstract

низмов аутоагрессии, этиопатогенез аутоиммунных заболеваний остается малоизученным, причем чет кую связь между развитием аутоиммунного заболе вания и появлением основных аутореактивных T лимфоцитов и аутоантител (ауто АТ) выявить уда ется далеко не всегда. Вместе с тем семействам ауто АТ с различными уровнями специфичности и функ циональности уделяется большое внимание. Такие семейства составляют сегодня важнейший объект исследований не только иммунологов, но и врачей клиницистов [1–6]. При аутоиммунных заболеваниях, включая ряд заболеваний ЩЖ, патогенетическая и клиническая значимость ауто АТ может существенно различаться [7–13]. В большей степени это относится к природ ным ауто АТ, которые обладают специфичностью в весьма широких пределах. К семейству таких ауто АТ принадлежат и каталитические ауто АТ (абзимы), потенциально готовые к реализации в организме ря да характерных для состояния аутоиммунной агрес сии эффекторных функций [14, 15]. Такие ауто АТ могут связывать различные антигены (АГ), начиная от внутриклеточных компонентов и заканчивая пе рекрестно реагирующими (мимикрирующими) микробными белками [15–17]. В настоящем обзоре анализируются имеющиеся в литературе данные от носительно роли и места ауто АТ в патогенезе ауто иммунного тиреоидита (АИТ) и болезни Грейвса (БГ) с перспективами использования ауто АТ, обла дающих различными уровнями специфичности и функциональности, в качестве молекулярных инструментов при решении врачом эндокриноло гом диагностических и прогностических задач.

Published
2007
Full Text
View/download PDF

16. Risk factors in cardiovascular patients: Challenges and opportunities to improve secondary prevention.

Author

Gabulova R, Marzà-Florensa A, Rahimov U, Isayeva M, Alasgarli S, Musayeva A, Gahramanova S, Ibrahimov F, Aliyev F, Imanov G, Rasulova R, Vaartjes I, Klipstein-Grobusch K, Graham I, and Grobbee DE

Abstract

Background: Effective management of major cardiovascular risk factors is of great importance to reduce mortality from cardiovascular disease (CVD). The Survey of Risk Factors in Coronary Heart Disease (SURF CHD) II study is a clinical audit of the recording and management of CHD risk factors. It was developed in collaboration with the European Association of Preventive Cardiology and the European Society of Cardiology (ESC). Previous studies have shown that control of major cardiovascular risk factors in patients with established atherosclerotic CVD is generally inadequate. Azerbaijan is a country in the South Caucasus, a region at a very high risk for CVD., Aim: To assess adherence to ESC recommendations for secondary prevention of CVD based on the measurement of both modifiable major risk factors and their therapeutic management in patients with confirmed CHD at different hospitals in Baku (Azerbaijan)., Methods: Six tertiary health care centers participated in the SURF CHD II study between 2019 and 2021. Information on demographics, risk factors, physical and laboratory data, and medications was collected using a standard questionnaire in consecutive patients aged ≥ 18 years with established CHD during outpatient visits. Data from 687 patients (mean age 59.6 ± 9.58 years; 24.9% female) were included in the study., Results: Only 15.1% of participants were involved in cardiac rehabilitation programs. The rate of uncontrolled risk factors was high: Systolic blood pressure (BP) (SBP) (54.6%), low-density lipoprotein cholesterol (LDL-C) (86.8%), diabetes mellitus (DM) (60.6%), as well as overweight (66.6%) and obesity (25%). In addition, significant differences in the prevalence and control of some risk factors [smoking, body mass index (BMI), waist circumference, blood glucose (BG), and SBP] between female and male participants were found. The cardiovascular health index score (CHIS) was calculated from the six risk factors: Non- or ex-smoker, BMI < 25 kg/m 2 , moderate/vigorous physical activity, controlled BP (< 140/90 mmHg; 140/80 mmHg for patients with DM), controlled LDL-C (< 70 mg/dL), and controlled BG (glycohemoglobin < 7% or BG < 126 mg/dL). Good, intermediate, and poor categories of CHIS were identified in 6%, 58.3%, and 35.7% of patients, respectively (without statistical differences between female and male patients)., Conclusion: Implementation of the current ESC recommendations for CHD secondary prevention and, in particular, the control rate of BP, are insufficient. Given the fact that patients with different comorbid pathologies are at a very high risk, this is of great importance in the management of such patients. This should be taken into account by healthcare organizers when planning secondary prevention activities and public health protection measures, especially in the regions at a high risk for CVD. A wide range of educational products based on the Clinical Practice Guidelines should be used to improve the adherence of healthcare professionals and patients to the management of CVD risk factors., Competing Interests: Conflict-of-interest statement: There is no conflict of interests to disclose. SURF II is conducted within the framework of the ESC Prevention of CVD Programme, led by the European Association of Preventive Cardiology (EAPC)., (©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results